Robert W. Baird downgrades Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) from Buy to Neutral, saying the latest Byetta update reduces their ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE